Emerson announced it has acquired Fluxa, a leader in the life sciences industry that uses software and modern technology architectures to accelerate the speed to market for new therapies, drugs and vaccines. The acquisition builds on Emerson’s software and solutions portfolio and life sciences expertise. In 2021 Emerson made an equity investment in Fluxa, which is based in Glendale, California. Fluxa accelerates the speed to market for new therapies by helping drug development and manufacturing organizations harness collaboration and data across sites, functions and processes. Emerson believes the acquisition of Fluxa’s PKM software, integrated with Emerson’s DeltaV control system and life sciences automation software, will provide customers a unique solution, accelerating the development of new drug therapies into production.
Veranese Promoted to CEO of AMI
With the continued growth and evolution of Advanced Manufacturing International, Inc. (AMI), the